ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0409

Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis

Lone Winter1, Dirk Skowasch1, Marcel Weber1, Daniel Kütting1, Charlotte Behning2, Peter Brossart3, Simon Petzinna4 and Valentin Sebastian Schäfer3, 1University Hospital Bonn, Bonn, Germany, 2Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany, 3Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, 4Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany

Meeting: ACR Convergence 2023

Keywords: Psoriatic arthritis, pulmonary, rheumatoid arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary impairment is a common, yet poorly understood, extraarticular manifestation in rheumatic diseases, which is often inadequately screened and managed. This can result in a substantial increase in morbidity and mortality [1]. While previous studies have mainly focused on rheumatoid arthritis (RA) and to some extent on psoriatic arthritis (PsA), data for patients with peripheral spondyloarthritis (pSpA) are lacking. The aim of this study was to investigate the prevalence of both clinical and subclinical pulmonary manifestations in newly diagnosed patients with RA, PsA, and pSpA. Furthermore, different baseline examination results were compared in order to develop a screening proposal for detecting patients at risk.

Methods: This clinical-prospective, longitudinal cohort study included a diagnostic workup consisting of a questionnaire for patient history, a physical examination, a body plethysmography with diffusion capacity for carbon monoxide (DLCO), a 6-minute walk test, laboratory parameters, and a chest x-ray (CXR) at the time of the initial diagnosis of arthritis disease, and at four additional time points in three-month intervals. This abstract thereby focuses on the baseline characteristics.

Results: In total 54 outpatients (26 RA, 24 PsA, 4 pSpA) and 26 age- and gender-matched controls were examined (tab. 1). Pulmonary impairment, in the sense of a morphologically abnormal CXR, was diagnosed in 19 arthritis patients (38.0 %). Of these, 36.8 % suffered from clinical symptoms such as cough and/or dyspnea. However, 63.2 % of the patients presented subclinical, asymptomatic pulmonary abnormalities (fig. 1). The baseline results of several examinations are illustrated in table 2. An elevation of rheumatoid factor ( > 14 IU/ml) showed an association with the manifestation of RA (p = .002) as well as with the presence of pulmonary affection (p = .008). In addition, the mean age of patients with pulmonary abnormalities (57.0 ± 12.8 yrs.) differed significantly from that of patients without such abnormalities (43.9 ± 14.3 yrs.), with a p-value of .002. The association between the activity of arthritis disease, assessed by Disease Activity Score in 28 joints using CRP (DAS28CRP), and CXR findings proved to be significant (p = .011). A DAS28CRP less than 3.2 (remission or low disease activity) indicated non-pathological findings in CXR.

Conclusion: The prevalence of pulmonary manifestations was more than one-third and more than two-thirds presented asymptomatic. The high proportion of asymptomatic patients highlights the need for the implementation of a pulmonary screening at the initial diagnosis of arthritis disease. By alerting physicians, especially in the observed age cohort of 57 years with elevated RF levels, morbidity and mortality could be reduced.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Winter: None; D. Skowasch: None; M. Weber: None; D. Kütting: None; C. Behning: None; P. Brossart: None; S. Petzinna: None; V. Schäfer: None.

To cite this abstract in AMA style:

Winter L, Skowasch D, Weber M, Kütting D, Behning C, Brossart P, Petzinna S, Schäfer V. Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-pulmonary-manifestations-in-patients-with-newly-diagnosed-rheumatoid-arthritis-psoriatic-arthritis-and-peripheral-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-pulmonary-manifestations-in-patients-with-newly-diagnosed-rheumatoid-arthritis-psoriatic-arthritis-and-peripheral-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology